GSK2033

Research use only, not for human use.

GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).

GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).(In Vitro):GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both SREBP1 and fatty acid synthase (FASN).(In Vivo):GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels .

GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXRα or full-length LXRβ cotransfection assays with IC50s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an ABCA1 driven luciferase reporter dose-dependently displaying IC50s of 52 nM for LXRα and 10 nM for LXRβ. GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1.

One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels.? Plasma triglyceride levels are also unaffected by treatment with GSK2033.

——

Others

Other Targets

——

——

——

1221277-90-2

591.66

C29H28F3NO5S2

>98% (HPLC)

In Vitro:?DMSO : 30 mg/mL (50.70 mM)

Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc1ccc(o1)C(F)(F)F)Cc1ccc(cc1)-c1cccc(c1)S(C)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years